ライフサイエンスコーパス: median overall survival

1 e frequency of FoxP3 cells did not influence median overall survival.

2 ociated with an improvement of 3.7 months in median overall survival.

3 ared with matched controls with de novo AML (median overall survival, 1.2 years v 2.9 years; P = .06)

4 herapy (HR 0.58 [95% CI 0.36-0.94], p=0.026; median overall survival 10.7 months [95% CI 6.5-18.9] vs

5 iotherapy (0.59 [95% CI 0.36-0.96], p=0.034; median overall survival 11.6 months [95% CI 6.5-20.5] vs

6 The latter was associated with a prolonged median overall survival (11.6 vs. 6.6 mo, P = 0.02).

7 and 336 in the docetaxel plus placebo group; median overall survival 12.6 months [95% CI 10.6-15.1] v

8 lso had improved survival with atezolizumab (median overall survival 12.6 months vs 8.9 months; HR 0.

9 fference in overall survival between groups (median overall survival 12.8 months [95.5% CI 10.5-14.3]

10 ee survival (11.1 months [95% CI 9.7-12.9]), median overall survival (25.6 months [23.1-34.3]), 1-yea

11 treatment medium entropy of less than 7.356 (median overall survival, 33.2 vs 11.7 months; P = .0002)

12 = .0002), coarse entropy of less than 7.116 (median overall survival, 33.2 vs 11.7 months; P = .0002)

13 , and medium uniformity of 0.007 or greater (median overall survival, 33.2 vs 11.7 months; P = .0002)

14 nk p=0.030), as well as significantly longer median overall survival (37.5 months [26-not reached] vs

15 rence (59 of 686 [8.6%]; P = .02) and longer median overall survival (75.9 months; P < .001).

16 nt groups in the overall patient population (median overall survival 8.8 months [95% CI 7.4-9.6] in t

17 Median overall survival after detection of intestinal me

18 Median overall survival after osimertinib progression wa

19 Median overall survival after radioembolization was 35 w

20 The median overall survival after resection was only 10 mo f

21 In the poor prognosis subgroup, median overall survival also did not differ between the

22 Median overall survival among relapsed/refractory patien

23 Median overall survival and conditional survival were 3.

24 Median overall survival and PFS for all patients were 25

25 Median overall survival and progression-free survival we

26 Median overall survival and progression-free survival, o

27 The median overall survival and treatment duration were 85.8

28 Median overall survival at clinical cutoff (1,337 deaths

29 The median overall survival based on periods of diagnosis we

30 squamous cell lung cancer (mSqCLC) increased median overall survival by 1.6 months (hazard ratio, 0.8

31 metastatic colorectal cancer that increases median overall survival by 6 weeks compared with placebo

32 The unadjusted median overall survival by facility volume was: Q1: 26.9

33 tients with WDTC was associated with shorter median overall survival compared with matched controls (

34 Radium-223 prolonged median overall survival compared with placebo, irrespect

35 rapy and biologic agents, at which point the median overall survival declines to 4-5 mo.

36 Median overall survival did not differ between patients

37 Median overall survival did not differ significantly bet

38 The median overall survival duration was significantly longe

39 The median overall survival for all 38 patients was 27.2 mon

40 Median overall survival for all patients following the f

41 The median overall survival for children with diffuse intrin

42 Median overall survival for CP-A patients was 13.3 mo (9

43 The median overall survival for patients in the gemcitabine

44 The median overall survival for patients with ETP-ALL/LBL wa

45 eived previous concurrent chemoradiotherapy, median overall survival for the 538 (65%) of 829 patient

46 Median overall survival for the entire cohort was 19 (95

47 Median overall survival for the ramucirumab group was 9.

48 ents with metastatic soft-tissue sarcoma and median overall survival for those treated is 12-16 month

49 Median overall survival for vorinostat was 30.7 weeks (9

50 The median overall survival from diagnosis was 17 months (95

51 Median overall survival from random assignment was 6.9 m

52 Median overall survival from the date of the first rando

53 With a median follow-up of 36.7 months, the median overall survival from the date of the first rando

54 The median overall survival from the first (90)Y treatment w

55 Median overall survival from the start of chemotherapy w

56 Median overall survival from the start of FOLFIRINOX ran

57 was evident in epithelioid histology, with a median overall survival gain of 5.4 months (HR, 0.70; 95

58 FS (GemErlo 11.4 months; Gem 11.4 months) or median overall survival (GemErlo 24.5 months; Gem 26.5 m

59 ration between 4 and 8 weeks had the longest median overall survival (group B: 40.4 months) compared

60 .5 months (range, 2.6+ to 22.3+ months), and median overall survival had not been reached (range, 4.6

61 6.8) for those assigned to ipilimumab alone; median overall survival had not been reached in either g

62 Median overall survival had not been reached in either g

63 At a minimum follow-up of 36 months, the median overall survival had not been reached in the nivo

64 an follow-up of approximately 23 months, the median overall survival has not been reached in either s

65 Median overall survival has not been reached.

66 Median overall survival has not yet been reached, with a

67 Median overall survival in 275 patients allocated EOC wa

68 Median overall survival in all patients (71% with two to

69 Median overall survival in all randomly assigned patient

70 f 50.3 months (IQR 32.9-68.0), the estimated median overall survival in group A has not been reached,

71 Median overall survival in group I, II, and III was 29,

72 Median overall survival in nivolumab-treated patients (6

73 In addition, median overall survival in ophthalmic-only disease was h

74 After 313 events, median overall survival in patients assigned nanoliposom

75 Median overall survival in patients who received cetuxim

76 ance therapy until progression, improved the median overall survival in patients with platinum-sensit

77 Median overall survival in TEA and TACE was 24.3 months

78 Based on pretreatment stratification data, median overall survival in the chemotherapy plus bevaciz

79 up, 81 in the active symptom control group), median overall survival in the docetaxel group was 5.2 m

80 Median overall survival in the intention-to-treat popula

81 The median overall survival in the OFF group (5.9 months; 95

82 Estimated median overall survival in the once-a-week arm was 39.5

83 Median overall survival in the per-protocol population w

84 er a median follow-up time of 11 months, the median overall survival in the RT cohort was 10.7 months

85 Median overall survival in the TCGA cohort was 1.9 years

86 Median overall survival in the total population was 23 m

87 The median overall survival in the UTSW cohort was significa

88 598 (91%) patients with BRAF(V600E) disease, median overall survival in the vemurafenib group was 13.

89 e 57 (9%) patients with BRAF(V600K) disease, median overall survival in the vemurafenib group was 14.

90 well tolerated and associated with promising median overall survival in these patients with heavily p

91 to 50.2% diagnosed in 1988 and 2010, and the median overall survival increased for both PTR and non-P

92 22.4 months (95% CI, 5.4 to 37.6 months) and median overall survival is 34.8 months (95% CI, 14.8 mon

93 l, rCBV was low in nine (47%) patients, with median overall survival (mOS) of 591 days, and high rCBV

94 n improved the outcomes of patients with HT (median overall survival, not reached v 1.7 years) but no

95 ard of care based on a 1.4-month increase in median overall survival observed in a randomized trial.

96 ll survival between treatment groups, with a median overall survival of 11.3 months (95% CI 9.5-13.4)

97 ol patients treated with dacarbazine (DTIC), median overall survival of 15.0 versus 8.3 months (P = 0

98 tio 1.06, 95% CI 0.88-1.29; p=0.527), with a median overall survival of 18.4 months (95% CI 15.6-22.1

99 h progression-free survival rate of 35%, and median overall survival of 23 months; grade 3 or 4 treat

100 normal AFP levels (<13 ng/dL) and exhibited median overall survival of 23.9 mo (95% CI, 20.1-124.1 m

101 ) across studies with a pooled patient-level median overall survival of 24.2 months (95% CI 21.7-26.8

102 creatic cancer treated with FOLFIRINOX had a median overall survival of 24.2 months-longer than that

103 -dose levels (10(8)-10(9) TCID50), and their median overall survival of 26.5 months compared favorabl

104 73 days, while untreated leukemic mice had a median overall survival of 34 days (P < .001, Mantel-Cox

105 total of 2698 patients were included with a median overall survival of 34 months (range 4-143).

106 This systematic review showed a median overall survival of 40% for patients with OHCA tr

107 rrence ranged from 133 to 2,428 days, with a median overall survival of 403 days.

108 0.87; 95% CI, 0.65 to 1.18; P = .188), with median overall survival of 43.9 months with letrozole ve

109 CP-B7 and >/=CP-B8 patients exhibited median overall survival of 6.9 mo (95% CI, 5.3-10.1 mo)

110 treated with 200 muCi (90)Y-DOTA-30F11 had a median overall survival of 73 days, while untreated leuk

111 The median overall survival of all 19 infused patients was 1

112 The median overall survival of all patients after the first

113 The median overall survival of all patients was 21.7 months

114 based therapies are often short lived with a median overall survival of months.

115 The prognosis of EMM is poor, and the median overall survival of patients who experience an ex

116 The median overall survival of PO patients was longer, when

117 mo (95% confidence interval [CI], 27-49 mo); median overall survival of the 89 patients left for mult

118 Survival analysis showed that the median overall survival (OS) and progression-free surviv

119 The median overall survival (OS) following cessation of ibru

120 The median overall survival (OS) for 60 patients was 12 year

121 The median overall survival (OS) for all t-AML/MDS patients

122 at baseline was significantly prognostic for median overall survival (OS) in univariate and multivari

123 atients with >3 CTC/ml had a trend for worse median overall survival (OS) than patients with 0.3-3 CT

124 Median overall survival (OS) time after diagnosis was 30

125 l (PFS) was 3.7 months (95%CI, 2.4 to 5) and median overall survival (OS) was 10.5 months (95%CI, 6.4

126 sponse duration was 8.3 and 10.7 months, and median overall survival (OS) was 16.5 and 13.6 months, r

127 For the total 41 patients, median overall survival (OS) was 18 mo (95% confidence i

128 Median overall survival (OS) was 26.9, 27.5, and 25.1 mo

129 The median overall survival (OS) was 30 months (95% confiden

130 The median overall survival (OS) was 40.1 months (range, 22.

131 Median overall survival (OS) was 6.9 and 6.1 months for

132 Median overall survival (OS) was 62.1 months and not rea

133 Median overall survival (OS) was not reached (median fol

134 Median overall survival (OS) was not reached for the FCR

135 The median overall survival (OS) was not reached in either a

136 ere 3 and 5.6 years (P = .26), respectively; median overall survival (OS) was not reached.

137 The median overall survival post-transformation was 5 years.

138 using point estimates for weighted values of median overall survival, progression-free survival, resp

139 The median overall survival rates were 19.5 months in arm A

140 The 10-month median overall survival shown in these studies for patie

141 Median overall survival since the start of second-line t

142 ly significant improvement of 11.8 months in median overall survival, suggesting a potential shift in

143 diation therapy plus chemotherapy had longer median overall survival than did those who received radi

144 arcopenic patients had significantly shorter median overall survival than nonsarcopenic patients (52.

145 ry, or distal CBD adenocarcinomas had longer median overall survival than those with PB type (71.7 vs

146 pectively (hazard ratio, 0.91; P = .18), and median overall survival time was 3.9 years in both treat

147 The median overall survival time was 36 months (95% CI, 25.2

148 The median overall survival time was 7.9 months (95% CI, 6.3

149 Median overall survival time was 9.1 months (95% CI, 6.1

150 ition of placebo, significantly improved the median overall survival to 56.5 months and extended the

151 The median overall survival was 1.035 years.

152 Estimated median overall survival was 1.43 years (95% confidence i

153 val was 4.1 months (95% CI, 1.5-6.5) and the median overall survival was 10.2 months (95% CI, 2.6-44.

154 Median overall survival was 10.4 months (95% CI 9.4-11.6

155 Median overall survival was 10.4 months for SRS alone an

156 In the total population, median overall survival was 10.4 months with pembrolizum

157 Median overall survival was 10.5 months (IQR 5.1-21.2) f

158 Median overall survival was 10.8 months for the entire p

159 n progression-free survival was 28.1 months; median overall survival was 101.7 months.

160 free survival was 61 d (range, 25-80 d), and median overall survival was 106 d (range, 37-417 d).

161 For the entire study cohort, median overall survival was 11.1 months (95% CI, 4.1-27.

162 Median overall survival was 11.2 months (95% CI 9.5-12.7

163 Median overall survival was 11.4 mo (95% confidence inte

164 ective response rate was 45% versus 31%, and median overall survival was 11.5 versus 8.5 months (HR,

165 Median overall survival was 11.6, 8.6, and 11.8 months;

166 l (PFS) was 3.6 months (95% CI, 2 to 4), and median overall survival was 11.8 months (95% CI, 8 to 25

167 In patients aged 70 years or older, median overall survival was 12.1 years (95% CI 10.5-13.7

168 The median overall survival was 12.2 months (95% confidence

169 Median overall survival was 12.6 years, and conditional

170 In the ST-PD and NT-PD groups, median overall survival was 13.0 and 16.7 months, respec

171 Median overall survival was 13.3 months (95% CI 12.4-14.

172 For colorectal cancer patients (n = 23), the median overall survival was 13.4 mo (95% CI, 8.2-15.7 mo

173 After a median follow-up of 28.9 months, the median overall survival was 13.6 months longer with ADT

174 d with atezolizumab compared with docetaxel (median overall survival was 13.8 months [95% CI 11.8-15.

175 nterval [CI], 0.91 to 1.45; P=0.25), and the median overall survival was 14.4 months versus 13.2 mont

176 The median overall survival was 14.5 mo (95% CI, 8.6-22.8 mo

177 Median overall survival was 143 days; older age (i.e., >

178 Median overall survival was 15.3 months after resection

179 Median overall survival was 15.7 months (95% CI 11.6-17.

180 umab (n=241) compared with docetaxel (n=222; median overall survival was 15.7 months [95% CI 12.6-18.

181 Median overall survival was 15.8 (95% CI, 13.0 to not av

182 Median overall survival was 15.9 months (10.4 to not est

183 Median overall survival was 15.9 months for doxorubicin

184 ths (IQR 5-11) and 210 deaths were reported; median overall survival was 16 months (95% CI 13-not ava

185 val was 6.0 (95% CI, 5.0 to 7.3) months, and median overall survival was 16.6 (95% CI, 11.1 to 20.6)

186 the ipilimumab followed by nivolumab group, median overall survival was 16.9 months (95% CI 9.2-26.5

187 rvival was 8.8 (95% CI, 4.6-15.4) months and median overall survival was 17.5 (95% CI, 13.3-NE) month

188 % CI 51.2-75.5) and, at a subsequent cutoff, median overall survival was 17.5 months (95% CI 13.7-not

189 Median overall survival was 17.7 months (95% CI 14.8-18.

190 Median overall survival was 17.7 years in CALR-mutant, 9

191 Median overall survival was 17.8 months (16.4-19.8) in t

192 Median overall survival was 18 mo after first radioembol

193 ion was 11 months (95% CI, 9-13 months), and median overall survival was 18 months (95% CI, 9-27 mont

194 Median overall survival was 18 months, with 1-, 3-, 5-,

195 Median overall survival was 18.1 years; 1-year, 3-year,

196 Median overall survival was 19.4 months (95% CI 16.4-26.

197 Median overall survival was 20 mo (interquartile range,

198 Median overall survival was 20.1 months (95% CI 16.7-23.

199 e in overall survival for patients with MRD: median overall survival was 20.1 months (95% CI 18.5-22.

200 Median overall survival was 21.4 months (95% CI 18.7-not

201 was 6.5 months (95% CI, 5.8 to 7.7 months); median overall survival was 21.5 months (95% CI, 16.0 to

202 Median overall survival was 22.3 months (95% CI 20.3-not

203 Median overall survival was 22.6 months in the primary-s

204 Median overall survival was 22.9 months (95% CI, 16.5 to

205 In LUX-Lung 6, median overall survival was 23.1 months (95% CI 20.4-27.

206 Median overall survival was 24.9 months (range: 4.9-85 m

207 Median overall survival was 25 months (95% CI, 12-32 mon

208 After the diagnosis of PM, median overall survival was 25 weeks (range, 3-193 weeks

209 Median overall survival was 25.1 months (95% CI 19.2-not

210 ing bortezomib and an immunomodulatory drug, median overall survival was 25.5 months (95% CI 19.6-34.

211 Median overall survival was 25.6 months (95% CI 22.5-29.

212 onths (T,: 16.6 months; TC, 5.6 months), and median overall survival was 25.7 months (T, not reached;

213 7.5 months (95% CI, 8.6-25.0 months) and the median overall survival was 25.8 months (95% CI, 15.7-25

214 Median overall survival was 26.3 months (95% CI 23.8-28.

215 Median overall survival was 26.5 months (20.9-31.7) with

216 Median overall survival was 27.3 months in patients who

217 tive tumours in either trial: in LUX-Lung 3, median overall survival was 27.6 months (19.8-41.7) in t

218 In LUX-Lung 3, median overall survival was 28.2 months (95% CI 24.6-33.

219 Median overall survival was 28.7 months (95% CI 24.1-36.

220 The median overall survival was 28.7 months, and the median

221 old for statistical significance [p<0.0095]; median overall survival was 29.8 months [95% CI 26.9-35.

222 76%) died after discontinuing ibrutinib; the median overall survival was 3.1 months after discontinua

223 a median follow-up of 45 months (IQR 35-58), median overall survival was 30 months (95% CI 24-34) in

224 The median overall survival was 30.0 months in the cetuximab

225 In treatment-naive patients, median overall survival was 31 months (95% CI, 24 to not

226 The median overall survival was 31.3 months (95% CI, 18.9-up

227 an follow-up of 20.7 months (IQR 14.2-25.4), median overall survival was 31.4 months (95% CI 28.6-not

228 therapy group in both trials: in LUX-Lung 3, median overall survival was 33.3 months (95% CI 26.8-41.

229 ture, although at the time of this analysis, median overall survival was 33.64 months (95% CI 31.34-n

230 Median overall survival was 34 months (95% CI, 27.1 to n

231 Median overall survival was 35 months (R0, 34 months; R1

232 o three risk categories using IMDC criteria, median overall survival was 35.3 months (95% CI 28.3-47.

233 Among propensity score-matched groups, the median overall survival was 37.3 (95% CI, 35.2-38.7) mon

234 Median overall survival was 40.3 months (95% CI 35.0-44.

235 Median overall survival was 43 months, median progressio

236 Median overall survival was 47.6 months (95% CI 42.5-not

237 s 14.7, 15.4, and 17.3 months, respectively; median overall survival was 49.8, 51.5, and 53.1 months,

238 Median overall survival was 5.2 months (IQR 2.3-9.9) in

239 o [HR], 1.05; 95% CI, 0.90 to 1.23), and the median overall survival was 50.8 and 59.1 months (HR, 0.

240 Median overall survival was 53.4 months.

241 The median overall survival was 56.5 months (95% confidence

242 LR only underwent salvage surgery, and their median overall survival was 58.6 months (95% CI, 28.8 to

243 te, 7%) to the next line of therapy, and the median overall survival was 6.3 months.

244 Median overall survival was 6.5 months, 9.0 and 5.1 mont

245 Median overall survival was 6.6 years (95% CI, 5.5 to 7.

246 iotherapy groups, respectively (p=0.58), and median overall survival was 6.9 months (95% CI 5.1-8.3)

247 The median overall survival was 61.2 (interquartile range [I

248 At the final analysis, median overall survival was 7.5 months (95% CI 6.4-8.5)

249 Median overall survival was 7.5 months in mesenchymal ve

250 0.45 [97.5% CI, 0.34 to 0.61]; P<0.001); the median overall survival was 7.7 months (95% CI, 6.0 to 9

251 The median overall survival was 7.7 months in the blinatumom

252 Median overall survival was 7.9 months (95% CI 6.7-9.5)

253 Median overall survival was 71 months (IQR 32 to not rea

254 Median overall survival was 75 weeks (IQR 25-not reached

255 rogression-free survival was 2.1 months, and median overall survival was 8 months.

256 % confidence interval, 0.35-0.92; P = .021); median overall survival was 8.0 vs 5.2 months, respectiv

257 As of Feb 1, 2014, median overall survival was 8.2 months (95% CI 6.1-10.1)

258 The median overall survival was 8.5 months in the nab-paclit

259 Median overall survival was 8.7 months (IQR, 3.6-16.8) w

260 Median overall survival was 8.8 months (95% CI 7.7-10.2)

261 The median overall survival was 8.8 months for Ona + Bev and

262 The median overall survival was 8.83 months (95% CI 7.11-11.

263 Median overall survival was 9.0 months (95% CI 6.8-10.9)

264 py did not provide a survival advantage; the median overall survival was 9.1 months (95% confidence i

265 The median overall survival was 9.2 months (95% confidence i

266 Median overall survival was 9.2 months for patients rand

267 the 16 patients with mast-cell leukemia, the median overall survival was 9.4 months (95% CI, 7.5 to n

268 Median overall survival was also longer in patients who

269 The median overall survival was also significantly improved

270 Median overall survival was an exploratory end point and

271 Median overall survival was improved for mDCF (18.8 v 12

272 Median overall survival was improved in the doublet arm

273 of overall survival with predefined factors, median overall survival was longer for: patients with ba

274 In this final descriptive analysis, median overall survival was longer with trastuzumab emta

275 Median overall survival was lower in PVRL (38.0 months;

276 was 9.1 months (95% CI, 4.9 to 11.7 months); median overall survival was not reached at 14 months.

277 ogression-free survival was 13.7 mo, and the median overall survival was not reached during follow-up

278 Median overall survival was not reached for treated pati

279 The median overall survival was not reached in either group

280 The median overall survival was not reached in either group.

281 Median overall survival was not reached in either pembro

282 an follow-up of 19.8 months (IQR 12.8-25.7), median overall survival was not reached in the nivolumab

283 an progression-free survival was 6.3 months; median overall survival was not reached.

284 n progression-free survival was 23.5 months; median overall survival was not reached.

285 rogression-free survival was 9.3 months, and median overall survival was not reached.

286 Median overall survival was not significantly different

287 Median overall survival was not significantly different

288 In the experimental arm, median overall survival was shorter (3.9 vs 6.7 months;

289 Across all patients, median overall survival was significantly longer if 7-mo

290 Median overall survival was significantly longer in pati

291 Median overall survival was significantly longer in the

292 Median overall survival was significantly longer in the

293 Similar to other cancers, the median overall survival was significantly shorter in pat

294 Median overall survival was similar between both arms wi

295 Median overall survival was superior in the salvage ASCT

296 Outcome by pathologic lymph node status (N, median overall survival) was N0: 224, 26 months; N1: 118

297 Median overall survivals were 18 months for the AZA grou

298 n a significant but only marginally improved median overall survival when combined with gemcitabine i

299 Dendritic cell-vaccinated patients showed a median overall survival with metastatic disease of 19.2

300 bjective was to test the hypothesis that the median overall survival would be 33.3% longer among pati